Amadeus Capital Partners’ Post

Pierre Socha, Amadeus Partner, puts the biotech public markets under the microscope in this European Life Sciences Review article🔬 Despite biotech IPO challenges, venture capital is fuelling innovation in AI and synthetic biology, with the latter poised to become a $30 billion industry by 2026. This surge is transforming healthcare delivery, making it more accessible outside conventional hospitals. We're proud to support these groundbreaking innovations, delivered by the pioneering founders we back 🤝 Read the article here⬇️ https://bit.ly/3z4HmRR #LifeSciences #HealthTech #VentureCapital

I am currently on my way to the Scottish Life Sciences Summit 2024, which is taking place in Aberdeen on March 20th. This is my first time attending this event, and I'm excited to see what it has in store. The summit promises to bring together investors, entrepreneurs and other industry leaders to explore how to transform innovative ideas into commercial realities. The main topics for discussion this year include: ➡️ Unlocking the power of genetic data ➡️ Exploring the future of AI and its applications in biotech ➡️ Understanding how venture capitalists make their investment choices in life sciences One of the hot topics expected to be discussed at the event is the use of AI to accelerate drug discovery, which is why I am eager to be there 😊 Have you had the opportunity to attend this forum before? #lifescience #clinicaldevelopment #biotech

🌟 Have you ever experienced an event that truly inspires #innovation? The Redefining Early Stage Investments #RESI Conference in Boston was just that! Here are three key takeaways that resonate with our mission to streamline drug #development for our clients: **Innovation through Collaboration:** The spotlight on cross-disciplinary partnerships was striking. By uniting #biotech, academia, and industry forces, we can supercharge research and fast-track innovative solutions to market! **Putting Patients First:** Key discussions underscored the critical role of early patient feedback in shaping development. This approach not only refines trial designs but ensures that our treatments genuinely address patient needs and enhance outcomes. **Harnessing Technology's Power:** Cutting-edge advancements in data analytics and AI are revolutionizing drug development. Utilizing these tools can sharpen decision-making, shorten timelines, and pave the way for greater success. As we tackle the complexities of #drugdevelopment ahead, these insights strengthen our resolve to empower clients in delivering transformative therapies where they’re needed most!

What a great event that was! We are still thrilled with the success of our first #biotechnology #conference: BioM's #BayOConnect! Bavaria showed its great potential of #ArtificialIntelligence and #data in medicine - uniting players from all areas of Bavarian and #international biotechnology. With 320 participants, 250 #partnering meetings, 15 #startup pitches, 20 exhibitors and over 30 sponsors and partners, BioM Biotech Cluster Development GmbH successfully promoted the new hotspot for #networking in the #biotech industry. Big players as Roche Deutschland, Google, Amazon Web Services (AWS) and NVIDIA, hidden champions and brilliant start-ups showed developments and innovative applications of #AI and big data for a new medicine - under watchful eyes of experts and #investors. Already mark you calendar! #BioM's BayOConnect will be back on stage next year on 👉 1-2 July 2025 👈! For impressions and if you want to know who won this year's BayOConnect #StartupAward (sponsored by Amazon Web Services) - here is a recap of this year's event. ➡️ https://lnkd.in/epGGGwiS #savethedate #Munich #biotechconference #biotechinnovation #innovationinBavaria #lifescience #research #funding #investment #venturecapital

I'm excited to be on the Diagnostics Panel at RESI in Boston on September 25 to talk about the risks, challenges, and path forward for investment in diagnostics. The past couple of years have been brutal for investment in diagnostics, and while our space is starting to recover, there are clear lessons to take from 2020-2022. 1) Investing in tools and kits, and investing in diagnostics, are not the same. Different customers, different markets, different challenges, different path to revenue and returns. 2) Great science, cool technology, concordant clinical validations do not mean there is a diagnostic test that 1) physicians will use to change how they practice or 2) that payors will pay for. If no one uses it, and/or no one pays for it, there is not a product. 3) Experience matters. Teams with no experience bringing clinical diagnostics to the market will have trouble anticipating timelines and capital requirements. 4) Boards can really mess up diagnostic companies. It's great to have big names, distinguished scientists, and blue chip investors on your board, but if you don't have anyone who can give expert guidance from experience, chances of success are lower. Try to find someone that can give clinical and commercial guidance, especially. Come join us! #diagnostics #RESIBoston #precisionmedicine #innovation

🔬 Join Us at RESI Boston for the Diagnostics Panel 🚀 The future of personalized medicine is rapidly evolving, and at RESI Boston, we're diving into the latest advancements in diagnostics. From IVD to genomics and precision medicine, this panel will explore the critical innovations driving the industry forward. 💡 Panel Highlights: Current Trends: Discover where the interest lies in today's diagnostics landscape. Challenges: Learn about the hurdles in navigating a competitive environment and how to overcome them. Investment Strategies: Get insights into successful fundraising and building investor relationships. Regulatory & Developmental Milestones: Understand the key obstacles and how to achieve critical milestones. Meet the Experts: Bruce Cohen - Xeraya Capital (Moderator) Nat Brinn - VC23 Deborah Hemingway, PhD - Ecphora Capital Hannah Mamuszka - 10Edison Capital James Murray - ExSight Ventures Soyoung Park - 1004 Venture Partners Don't miss this chance to gain valuable insights from industry leaders on how to successfully navigate the diagnostics ecosystem. Whether you're a startup looking to fundraise or an established company seeking to stay ahead of the curve, this panel is a must-attend! Register: https://lnkd.in/e7QS-AZi #RESIBoston #Diagnostics #PersonalizedMedicine #Innovation #InvestingInHealthcare

🔍 Insights from Matthias Kromayer at BayOConnect in Munich! 🔍 This week, Matthias Kromayer held a presentation at BayOConnect by BioM Biotech Cluster Development GmbH. Under the theme "Reflections on AI from an Agnostic VC Investor," Matthias shared MIG Capital’s reflections on the potential impact of #AI within the #biopharma value chain. Key points included: 🚀 The Fight: Understanding the role of AI in revolutionizing clinical trials. 📊 Analysis: Breaking down AI’s potential in enhancing trial design, site selection, real-time monitoring, and patient experiences. 🔍 Conclusion: Assessing AI’s transformative power across the biopharma value chain, from early development to market approval. #BayOConnect2024 was fun – see you next year! 💡 Bayerisches Staatsministerium für Wirtschaft, Landesentwicklung und Energie | Roche Deutschland

In any given moment, we have two options: to step forward into growth or step back into safety - Abraham Maslow As the #pharmaceutical industry is experiencing a revolution driven by artificial intelligence and massive computing power, this decision is more critical than ever.… If #AI simplifies work by analyzing, filtering, sorting, predicting and recognizing huge volumes of data, ELEM’s #virtualhumans, developed in Barcelona Supercomputing Center's MareNostrum and deployed in a supercomputing cloud, are revolutionizing therapeutics development and patient prognosis, enabling large-scale reliable in-silico #clinicaltrials.  To step forward into the future of healthcare with ELEM, contact us at contact@elem.bio and request a demo of our platform. The future is now! #medtech #Healthtech #EUeic

Wet labs and life science hubs have significantly impacted our industry, facilitating the commercialization of innovations and supporting research and development. These facilities are essential for fostering collaboration and enabling scientists to conduct cutting-edge research.   Join BioNTX at the iC³ Life Science Summit for an engaging session exploring these critical spaces and their role in shaping the biotech landscape. We will focus on the emerging ecosystem of innovative environments like BioLabs Pegasus Park - North Texas, JLABS at the Texas Medical Center, Profound Ventures, LLC’ Social Impact Venture Studio, and their vital infrastructure and community building for successful new healthcare and life science ventures.   Attendees will gain insights into the design, management, and operation of these facilities, which are key to advancing biotechnology research and driving industry growth.   Register now https://lnkd.in/gxKSDt5b #research #healthcare #bioscience #biotech #lifescience #biotechnology #innovation #biomanufacturing #facilities #lab #wetlabs #Texas #NorthTexas #ecosystem #commercialization #collaboration

As promised, I'm starting with some very interesting life-science- and biotech startups. Starting with AdRegeneer. 🚀 Revolutionizing Regenerative Medicine: Meet AdRegeneer! Have you ever wondered what it takes to truly transform the field of regenerative medicine? AdRegeneer is doing just that, and their journey is nothing short of inspiring. At #Curious2024, I had the pleasure of meeting the brilliant minds behind AdRegeneer, a startup dedicated to filling a critical void in the medical landscape. Their mission? To provide innovative treatments that promote axonal regrowth and remyelination – therapies that are currently unavailable elsewhere. Imagine a world where nervous system injuries and disorders are no longer a life sentence. AdRegeneer is making this a reality with their groundbreaking research and cutting-edge solutions. Read the full post and see the video here: Mert Duman